Sitaram Siddharth, holding the position of interim PAO at Doximity, Inc. (NYSE:DOCS), disclosed multiple securities transactions on June 8, 2026, per a recent filing with the Securities and Exchange Commission. The filing detailed the disposition of 2,444 shares of Class A Common Stock, generating proceeds of $49,882. The shares were sold at an average price of $20.41 per unit. At the time of the transaction, the stock was trading at $20.23, a level that sits close to its 52-week low of $17.15. Over the trailing twelve months, the equity has declined by 65%. Despite this performance, InvestingPro analysis suggests the shares may be trading below their intrinsic fair value, positioning Doximity among stocks identified as potentially undervalued.
The sale executed by Siddharth was classified as a "sell-to-cover" transaction. This mechanism is typically used to satisfy tax withholding obligations that arise when stock options are exercised. The transaction was not discretionary but was carried out automatically under a Rule 10b5-1 trading plan. Siddharth established this pre-arranged trading framework on August 28, 2025, which allows for regular, automated execution of trades regardless of short-term market movements.
Earlier on the same day, Siddharth acquired 5,000 shares of Class A Common Stock. This increase in holdings resulted from the conversion of an equivalent number of Class B Common Stock shares. The conversion process operates at the holder's option, with each Class B share converting into one Class A share. The underlying Class B shares were originally obtained through the exercise of a stock option granted on December 22, 2020. This option carried an exercise price of $4.12 per share, and the associated shares have been vesting over time since November 23, 2021.
Following the completion of these reported transactions, Sitaram Siddharth's direct ownership in Doximity Class A Common Stock stands at 90,706 shares. The stock price data indicates a closing price of $20.23, representing a decline of $0.22 or 1.08% from the previous close. After-hours trading showed a price of $20.24 with no change.
In related corporate developments, Doximity reported its fiscal fourth-quarter financial results. The company achieved a slight beat in both revenue and adjusted EBITDA. However, the company issued new fiscal 2027 revenue guidance ranging from $664 million to $676 million. This guidance indicates an expected growth rate of approximately 3% to 5%. This projection falls below the Street's current consensus expectation of $699 million.
Analysts have responded to these developments with various adjustments to their price targets for Doximity. BofA Securities lowered its price target to $38 from $47, while maintaining a Buy rating. The firm cited concerns regarding growth prospects and structurally lower margins. BMO Capital reduced its price target to $20 from $25, maintaining a Market Perform rating due to macroeconomic headwinds and costs associated with artificial intelligence. Mizuho adjusted its price target to $26 from $34, citing a weaker growth outlook for fiscal 2027. Canaccord revised its price target to $30 from $34, maintaining a Buy rating, following concerns about pharmaceutical budget constraints. Piper Sandler, however, reiterated an Overweight rating with a $42 price target, highlighting the artificial intelligence opportunity despite the challenging macro environment.